We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
In the latest close session, Johnson & Johnson (JNJ - Free Report) was up +2.01% at $271.19. This change outpaced the S&P 500's 0.71% loss on the day. Meanwhile, the Dow lost 0.79%, and the Nasdaq, a tech-heavy index, lost 1.03%.
Shares of the world's biggest maker of health care products have appreciated by 4.5% over the course of the past month, outperforming the Medical sector's gain of 4.16%, and the S&P 500's gain of 2.72%.
The investment community will be paying close attention to the earnings performance of Johnson & Johnson in its upcoming release. The company is slated to reveal its earnings on October 13, 2026. The company's earnings per share (EPS) are projected to be $2.95, reflecting a 5.36% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $25.36 billion, indicating a 5.71% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.59 per share and a revenue of $101.09 billion, signifying shifts of +7.41% and +7.32%, respectively, from the last year.
Any recent changes to analyst estimates for Johnson & Johnson should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.72% lower. Currently, Johnson & Johnson is carrying a Zacks Rank of #3 (Hold).
In the context of valuation, Johnson & Johnson is at present trading with a Forward P/E ratio of 22.94. This denotes a premium relative to the industry average Forward P/E of 17.2.
It's also important to note that JNJ currently trades at a PEG ratio of 2.54. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.61.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 97, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
In the latest close session, Johnson & Johnson (JNJ - Free Report) was up +2.01% at $271.19. This change outpaced the S&P 500's 0.71% loss on the day. Meanwhile, the Dow lost 0.79%, and the Nasdaq, a tech-heavy index, lost 1.03%.
Shares of the world's biggest maker of health care products have appreciated by 4.5% over the course of the past month, outperforming the Medical sector's gain of 4.16%, and the S&P 500's gain of 2.72%.
The investment community will be paying close attention to the earnings performance of Johnson & Johnson in its upcoming release. The company is slated to reveal its earnings on October 13, 2026. The company's earnings per share (EPS) are projected to be $2.95, reflecting a 5.36% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $25.36 billion, indicating a 5.71% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.59 per share and a revenue of $101.09 billion, signifying shifts of +7.41% and +7.32%, respectively, from the last year.
Any recent changes to analyst estimates for Johnson & Johnson should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.72% lower. Currently, Johnson & Johnson is carrying a Zacks Rank of #3 (Hold).
In the context of valuation, Johnson & Johnson is at present trading with a Forward P/E ratio of 22.94. This denotes a premium relative to the industry average Forward P/E of 17.2.
It's also important to note that JNJ currently trades at a PEG ratio of 2.54. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.61.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 97, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.